Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P00750 (
PLA
)
16,800
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related mortality worldwide. We have previously reported that
LASP-1
is a downstream protein of the urokinase type
plasminogen activator
(uPA). Here we investigated the role of
LASP-1
in HCC by a molecular and biological characterization of
LASP-1
expression in human HCC specimens and in cultured HCC cells. We determined the
LASP-1
mRNA expression levels in 55 HCC cases with different hepatic background disease. We identified 3 groups of patients with high, equal or low
LASP-1
mRNA levels in HCC tissues compared to the peritumoral (PT) tissues. In particular we found that i) the HCCs displayed a higher
LASP-1
mRNA level in HCC compared to PT tissues; ii) the expression levels of
LASP-1
mRNA in female HCCs were significantly higher compared to male HCCs; iii) the cirrhotic HCCs displayed a higher
LASP-1
mRNA. Further, the biological characterization of the ectopic
LASP-1
overexpression in HCC cells, using MALDI-TOF mass spectrometer on the
LASP-1
co-immunoprecipitated fractions, displayed vimentin as a novel putative partner of
LASP-1
. Our results suggest that
LASP-1
mRNA overexpression may be mainly implicated in female HCCs and cirrhotic HCCs; and that LASP1 may play its role with vimentin in HCC cells.
...
PMID:Molecular characterization of LASP-1 expression reveals vimentin as its new partner in human hepatocellular carcinoma cells. 2576 Jun 90